<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ETONOGESTREL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ETONOGESTREL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception (no hormonal contraceptive use in previous month)</span>,
            </h4>
            <p class="specificity"><span class="route">By subdermal implantation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 implant inserted during first 5 days of cycle, implant should be removed within 3 years of insertion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception (postpartum)</span>,
            </h4>
            <p class="specificity"><span class="route">By subdermal implantation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 implant to be inserted 21&#8211;28 days after delivery, 1 implant to be inserted after 28 days postpartum in breast-feeding mothers, implant should be removed within 3 years of insertion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception following abortion or miscarriage in the second trimester</span>,
            </h4>
            <p class="specificity"><span class="route">By subdermal implantation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 implant to be inserted 21&#8211;28 days after abortion or miscarriage, implant should be removed within 3 years of insertion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception following abortion or miscarriage in the first trimester</span>,
            </h4>
            <p class="specificity"><span class="route">By subdermal implantation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 implant to be inserted within 5 days, implant should be removed within 3 years of insertion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception (changing from other hormonal contraceptive)</span>,
            </h4>
            <p class="specificity"><span class="route">By subdermal implantation</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                Implant should be removed within 3 years of insertion (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful, remove implant if pregnancy occurs.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Acute porphyria</li>
            <li>history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable</li>
            <li>severe arterial disease</li>
            <li>undiagnosed vaginal bleeding</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Breast discomfort, changes in libido, depression, disturbance of appetite, dizziness, headache, injection-site reactions, menstrual irregularities, nausea, vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Cervical cancer</h3>
              <p>Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives. The risk of cervical cancer with other progestogen-only contraceptives is not yet known.</p>
            </section>
            <section class="advice">
                <h3>Breast cancer</h3>
              <p>There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Full counselling backed by patient information leaflet required before administration.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
            arterial disease
          </li>
          <li>
            disturbances of lipid metabolism
          </li>
          <li>
            history during pregnancy of deterioration of otosclerosis
          </li>
          <li>
            history during pregnancy of pruritus
          </li>
          <li>
            history of jaundice in pregnancy
          </li>
          <li>
            malabsorption syndromes
          </li>
          <li>
            possible risk of breast cancer
          </li>
          <li>
            sex-steroid dependent cancer
          </li>
          <li>
            systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ETONOGESTREL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP97384"><a href="../medicinalForm/PHP97384.html" data-target="#PHP97384" data-action="load">Implant</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
